Kiora Pharmaceuticals (NASDAQ:KPRX) vs. Critical Outcome Technologies (OTCMKTS:COTQF) Financial Contrast

Critical Outcome Technologies (OTCMKTS:COTQF) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Insider & Institutional Ownership

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Critical Outcome Technologies and Kiora Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Critical Outcome Technologies	0	0	0	0	0.00
Kiora Pharmaceuticals	1	1	1	0	2.00

Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 429.10%. Given Kiora Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Critical Outcome Technologies.

Earnings & Valuation

This table compares Critical Outcome Technologies and Kiora Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals	$16.02 million	0.47	-$10.84 million	($2.65)	-0.71

Critical Outcome Technologies has higher earnings, but lower revenue than Kiora Pharmaceuticals.

Profitability

This table compares Critical Outcome Technologies and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Critical Outcome Technologies	N/A	N/A	N/A
Kiora Pharmaceuticals	N/A	-51.37%	-36.09%

Summary

Kiora Pharmaceuticals beats Critical Outcome Technologies on 6 of the 8 factors compared between the two stocks.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.